RxDoctor Payments Data

Kevin Tomera, MD

Urology · Beloit, WINPI 1255385258

Payments from drug & device makers

$1,523in general payments, 2019–2025

Across 40 payments — averaging $38.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$361
  • Johnson & Johnson$229
  • Boston Scientific$175
  • Astellas Pharma US Inc$124
  • Janssen Scientific Affairs, LLC$115
  • Merck$90
  • plus $430 from 11 others

What the payments were for

  • Food & beverage$1,49498%
  • Education$292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,523 in reported general payments places this provider in the 60th percentile of 215 urology providers in Wisconsin.

See all urology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$181,721
Medicare patients
493
Services billed
1,834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron47$33,098
Oxybutynin Chloride ErOxybutynin Chloride195$5,248
Tamsulosin Hcl314$4,030
Finasteride264$2,924
Silodosin39$2,734
Dutasteride80$2,522
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst103$1,154
Solifenacin Succinate29$773
Doxazosin Mesylate48$549
Oxybutynin Chloride29$501
Terazosin Hcl12$472
Imipramine Hcl21$293
Cephalexin42$287
Alfuzosin Hcl ErAlfuzosin Hcl17$275
Ampicillin Trihydrate13$168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$124$33,09847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 215 urology providers in Wisconsin.

Other urology in Beloit

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →